Mycophenolate mofetil to the rescue in autoimmune hepatitis: A fresh sprout on the decision tree  by Czaja, Albert J.
www.elsevier.com/locate/jhep
Journal of Hepatology 51 (2009) 8–10Editorial
Mycophenolate mofetil to the rescue in autoimmune hepatitis:
A fresh sprout on the decision treeq
Albert J. Czaja*
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, MN 55905, USASee Article, pages 156–160The concept that some patients with autoimmune
hepatitis may not respond well to corticosteroid therapy
can be diﬃcult to accept. Success breeds complacency,
and few treatments of chronic liver disease have been
as successful as corticosteroid therapy. Prednisone alone
or a lower dose in combination with azathioprine
induces clinical, laboratory and histological improve-
ment in 80% of adults with autoimmune hepatitis within
3 years [1–4], normalizes 10- and 20-year life-expectan-
cies [5], and prevents or reduces hepatic ﬁbrosis in
79% [6]. Similar but less comprehensive results have
been reported in children [7–9], and expectations of
treatment success are justiﬁably high in both patient
populations. The report by Aw and colleagues that
14% of children fail to respond or tolerate corticosteroid
treatment [10] complements the experience in adults
[11,12], and it is an important reality check. Not only
does it re-conﬁrm the need for a rescue therapy in auto-
immune hepatitis, but it also strengthens the support for
mycophenolate mofetil in this role [10].
Mycophenolate mofetil is a prodrug hydrolyzed by
liver esterases to produce the active metabolite, myco-
phenolic acid, which in turn acts as a non-competitive,
reversible inhibitor of inosine monophosphate dehydro-
genase [13–16]. Inosine monophosphate dehydrogenase
is the rate-limiting enzyme for de novo synthesis of pur-
ines, and by inhibiting its action, mycophenolate mofetil0168-8278/$36.00  2009 European Association for the Study of the Liver.
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B cells to antigens. Mycophenolate mofetil is a purine
antagonist like azathioprine, but its potent immunosup-
pressive actions and independence from the thiopurine
methyltransferase pathway of catabolism enhance its
appeal as a more powerful and better tolerated agent
than azathioprine [13–16].
Aw and colleagues indicate that 18 of 26 children
with problematic autoimmune liver disease (69%) had
complete or partial laboratory resolution after therapy
with mycophenolate mofetil and that all were alive
3.5–7.6 years (median, 6.7 years) from the onset of treat-
ment [10]. These frequencies of improvement and trans-
plant-free survival are presumably greater than would
have been expected if mycophenolate mofetil had not
been instituted, and they are similar to the outcomes
in adults who have been treated with the same drug
under comparable clinical circumstances [17–24].
Improvements of varying degree and nature have
occurred in 31–84% of similarly distressed and treated
adults [17–24].
Nine small, single-institution, retrospective experi-
ences now support the use of mycophenolate mofetil
as a second-line treatment for autoimmune hepatitis
[10,17–24]. The number and size of these studies attest
to the rarity of refractory disease in single institutions,
the diﬃculty of performing rigorous treatment trials in
this select patient population, and the urgent need for
rescue therapy. This latter aspect of patient care can
trump the call (and wait) for collaborative prospective
treatment trials, and mycophenolate mofetil is already
inﬁltrating the therapeutic arsenal of autoimmune hepa-
titis [17]. As Aw and colleagues wisely recommend,Published by Elsevier B.V. All rights reserved.
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domized clinical trials [10], but the reality of clinical
practice threatens to supersede this advice [17].
The oﬀ-label institution of therapy with mycopheno-
late mofetil is a bold step. The unorthodoxy and empir-
icism of the treatment are commonly compounded with
inexperience in its administration. Accordingly, the deci-
sion for oﬀ-label treatment demands a sober, highly
individualized analysis, preferably by an experienced
hepatologist in a tertiary medical center, ideally within
the context of a clinical trial. The appropriate target
population, dosing schedule, monitoring sequence, and
safety proﬁle are uncertain, and even the event that
requires rescue is unclear.
The minimum level of residual disease activity that is
tolerable long term is uncertain in autoimmune hepati-
tis, and treatment with mycophenolate mofetil for an
incomplete response to corticosteroid therapy may not
represent a true salvage situation. Mild liver inﬂamma-
tion can be non-progressive if conventional therapy is
continuous and dose-adjusted to disease behavior
[25,26]. Disease progression rather than controlled per-
sistence may be the most appropriate signal for rescue.
Similarly, a patient’s intolerance of one medication
does not imply that the introduction of another less
established, more expensive drug will ameliorate the sit-
uation. Six to 34% of adults in need of rescue are unable
to tolerate mycophenolate mofetil because of nausea,
headache, vomiting, pancreatitis, rash, alopecia, deep
venous thrombosis, and diarrhea [22–24], and 13 of 26
children treated by Aw and colleagues [10] experienced
side eﬀects, including four in whom the medication
had to be stopped (15%), presumably because of leuko-
penia and neutropenia.
Combined results from the four most recent reports
indicate that treatment with mycophenolate mofetil is
complicated by drug intolerance in 18% and an incom-
plete or non-response in 50% [10,21–24]. These ﬁndings
underscore the need for codiﬁed indications for salvage
therapy and conﬁdent dosing schedules before this treat-
ment can be designated appropriate and safe. Myco-
phenolate mofetil is 6–14 times more expensive than
azathioprine [27–29], and its inconsistent record of eﬃ-
cacy and safety argue for discretion and precaution in
its oﬀ-label use [10,21–24].
Progress has been made in identifying patients with
autoimmune liver disease who will not respond to ther-
apy with mycophenolate mofetil, but additional charac-
terizations are necessary to target the treatment and
conserve resources. Six of the 8 children in the study
of Aw and colleagues who could not be rescued by
mycophenolate mofetil had autoimmune sclerosing cho-
langitis [10]. This experience in children is similar to that
in adults with primary sclerosing cholangitis [30,31], and
it should avert the fruitless administration of an expen-
sive, potentially toxic, medication to this subgroup.Hennes and colleagues also provide guidelines in
selecting the adult subset best suited for rescue with
mycophenolate mofetil [23]. Six of 8 adults with prior
non-response to azathioprine could not be rescued with
mycophenolate mofetil, whereas 12 of 28 patients (43%)
with intolerance to azathioprine improved [23]. In this
experience, patients were rescued from their original
medication rather than their liver disease. Additional
analyses of a similar nature are necessary to optimize
the use of mycophenolate mofetil in autoimmune hepa-
titis. They promise to improve the eﬃcacy of the drug by
restricting its use. As the number of candidates for res-
cue with mycophenolate mofetil shrinks, an urgent call
for other rescue agents can be anticipated.
The study by Aw and colleagues underscores the need
for rescue therapy in autoimmune hepatitis, and it
deﬁnes the subset of children in whom mycophenolate
mofetil is likely to help [10]. It also highlights the impor-
tance of an evolving area of investigation in autoim-
mune hepatitis where the deﬁciencies of conventional
therapy are recognized and new options for distressed
subgroups are developed. This area must be fortiﬁed
so that collaborative investigative networks can be nur-
tured and new treatments can be evaluated quickly and
reliably. Mycophenolate mofetil must earn a place in the
treatment algorithm for both children and adults with
autoimmune hepatitis by organized prospective clinical
trials rather than acclamation. Until then, its branch
on the decision tree is fragile.References
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